Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patientsECCO '17 Barcelona
Year: 2017
Authors:

Ladic A., Bozina N., Cukovic-Cavka S., Krznaric Z.

University Hospital Centre Zagreb, Zagreb, Croatia

P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?ECCO '17 Barcelona
Year: 2017
Authors:

Piotrowicz G.*1, Kowerzanow J.2, Banaszkiewicz P.2, Babicki A.2, Kot J.3, Rydzewska G.4

1Self-Dependet Health Care Unit of Ministry of Iterior, Gastroenetrology, Gdansk, Poland 2Self-Dependent Health Care Unit of Ministry of Interior, Surgery, Gdansk, Poland 3UCMMiT, Clinic Hyperbaric Medicine and Sea Rescue, Gdynia, Poland 4Central Clinical Hospital of the Ministry of Interior of Warsaw, Gastroenterology, Warsaw, Poland

P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriersECCO '17 Barcelona
Year: 2017
Authors:

Bryant R.*1,2, Costello S.1,3, Schoeman S.4, Sathananthan D.4, Lau S.3, Schoeman M.4, Mountifield R.1,5, Tee D.6, Travis S.7,8, Andrews J.1,9

1University of Adelaide, School of Medicine, Adelaide, Australia 2Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia 3Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia 4Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia 5Flinders Medical Centre, Department of Gastroenterology, Adelaide, Australia 6Lyell McEwin Hospital, Department of Gastroenterology, Adelaide, Australia 7Oxford University Hospital NHS Trust - John Radcliffe Hospital, Department of Transitional Gastroenterology, Oxford, United Kingdom 8University of Oxford, Oxford, United Kingdom 9Royal Adelaide Hospital, Department of Gastroenteorlogy and Hepatology, Adelaide, Australia

P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Hartery K., Moran C., Sheridan J., Keegan D., Byrne K., Horgan G., Doherty G., Cullen G., Buckley M., Mulcahy H.

St. Vincent's University Hospital, Gastroenterology Department, Dublin, Ireland

P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutationECCO '17 Barcelona
Year: 2017
Authors:

Zambrano Perez A.*1, Elawad M.2, Kiparissi F.1, Shah N.1, Chadokufa S.1, Sider S.1, Huggett B.1

1Great Ormond Street Hospital for Children, Department of Gastroenterology, London, United Kingdom 2Sidra Medical and Research Center, Inflammatory Bowel Disorders Section, Doha, Qatar

P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” studyECCO '17 Barcelona
Year: 2017
Authors:

Balint A.*1, Torocsik D.1, Palatka K.2, Szepes Z.1, Szucs M.3, Ferenci T.4, Nagy F.1, Farkas K.1, Fábián A.1, Bor R.1, Milassin A.1, Rutka M.1, Molnar T.1

1University of Szeged, First Department of Medicine, Szeged, Hungary 2University of Debrecen, Department of Internal Medicine II, Debrecen, Hungary 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary 4Óbuda University, John von Neumann Faculty of Informatics, Budapest, Hungary

P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Scaioli E., Sartini A., Bellanova M., Campieri M., Festi D., Bazzoli F., Belluzzi A.

S Orsola Malpighi Hospital-University of Bologna, Department of Medical and Surgical Sciences, Gastroenterology Unit, Bologna, Italy

P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016ECCO '17 Barcelona
Year: 2017
Authors:

Han S., Kim S., Kim J., Kwon D.-H., Choi J.-S., Yoon S.-R., Yun S.-H., Kim D.-S., Bae J.-H., Choi H.-J., Sung H.-Y., Yoon S.-W.

Celltrion Healthcare Co., Ltd, Incheon, South Korea

P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN studyECCO '17 Barcelona
Year: 2017
Authors:

Barreiro-de Acosta M.*1, Iborra M.2, García V.3, Gutiérrez A.4, Garcia S.5, Domènech E.6, Martín Arranz M.D.7, Cea-Calvo L.8, Romero C.8, Juliá B.8

1Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain 2Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain 3Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain 4Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain 5Departamento de Gastroenterología, Hospital Miguel Servet, Zaragoza, Spain 6Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain 7Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain 8MSD Spain, Medical Department, Madrid, Spain

P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?ECCO '17 Barcelona
Year: 2017
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

1Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark 2Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark

P585: Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategyECCO '17 Barcelona
Year: 2017
Authors:

Sambuelli A.*1, Bellicoso M.2, Negreira S.2, Goncalves S.2, Huernos S.2, Chavero P.2, Tirado P.2, Cabanne A.3, Gil A.2

1Hospital Bonorino Udaondo, IBD Section - Medicine, Buenos Aires, Argentina 2IBD Section - Hospital Bonorino Udaondo, Medicine, Buenos Aires, Argentina 3Hospital Bonorino Udaondo, Pathology Department, Buenos Aires, Argentina

P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experienceECCO '17 Barcelona
Year: 2017
Authors:

Plevris N., Deekae A., Jones G.R., Manship T.A., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controlsECCO '17 Barcelona
Year: 2017
Authors:

McGowan M.1, Kokkorou M.2, Rebull M.1, Koh Y.3, Gaya D.R.4, Hansen R.5, Russell R.K.5, Gerasimidis K.*1

1University of Glasgow, Human Nutrition, Glasgow, United Kingdom 2University Of Glasgow, Human Nutrition, Glasgow, United Kingdom 3University of Glasgow, Glasgow, United Kingdom 4Glasgow Royal Infirmary, Gastroenterology Unit, Glasgow, United Kingdom 5The Royal Hospital for Children Glasgow, Paediatric Gastroenterology, Glasgow, United Kingdom

P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54ECCO '17 Barcelona
Year: 2017
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

1Asklepios Westklinikum Hamburg, Gastroenterology, Hamburg, Germany 2Christian Albrechts University Kiel, Department of Internal Medicine I, Kiel, Germany

P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Paramsothy S.*1,2, Paramsothy R.3, Kamm M.4, Kaakoush N.5, Mitchell H.6, Rubin D.2, Castaño-Rodríguez N.6

1University of New South Wales, St Vincent's Clinical School, Sydney, Australia 2University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States 3Liverpool Hospital, Department of Gastroenterology, Sydney, Australia 4St Vincent's Hospital, University of Melbourne, Departments of Gastroenterology and Medicine, Melbourne, Australia 5University of New South Wales, School of Medical Sciences, Sydney, Australia 6University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia

P590: Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)ECCO '17 Barcelona
Year: 2017
Authors:

Sebastian S.*1, Lewis J.D.2, Siegmund B.3, Wolf D.4, Siegel C.A.5, Lichtenstein G.2, Louis E.6, Hebuterne X.7, Ginsburg P.M.8, Ostrov A.9, Ricci M.Q.10, Bernsen M.11, Shafran I.12, Nancey S.13, Moran G.14, Teich N.15, Lal S.16, Kiszka-Kanowitz M.17, Murugesan S.18, Moum B.19, Dolin P.20

1Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom 2University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, United States 3Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany 4Atlanta Gastroenterology Associates, Atlanta, United States 5Dartmouth-Hitchcock Medical Center, Departmnet of Gastroenterology, Lebanon, United States 6CHU Liège, Liège, Belgium 7CHU Archet 2, Department of Gastroenterology, Nice, France 8Gastroenterology Center of Connecticut, Hamden, United States 9Saratoga Schenectady Gastro Associates, Burnt Hills, United States 10Middlesex Gastroenterology Associates, Middletown, United States 11Illinois Gastroenterology Group, Arlington Heights, United States 12Shafran Gastroenterology Center, Winter Park, United States 13CHU Lyon, Department of Gastroenterology, Lyon, France 14Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom 15Internistische Gemeinschaftspraxis, Department of Gastroenterology, Leipzig, Germany 16Salford Royal NHS Foundation Trust, Department of Gastroenterology, Salford, United Kingdom 17Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark 18Blackpool Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology, Blackpool, United Kingdom 19Oslo University, Department of Gastroenterology, Oslo, Norway 20Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

P591: Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approachECCO '17 Barcelona
Year: 2017
Authors:

Chadokufa S.*1, Sider S.1, Huggett B.1, Sawney T.1, Shah N.1, Baycheva M.1, Zambrano Perez A.1, Acton N.1, Kiparissi F.1,2

1Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom 2University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P592: Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohortECCO '17 Barcelona
Year: 2017
Authors:

Lovasz B.D.*1, Kurti Z.1, Rutka M.2, Vegh Z.1, Gecse K.B.1, Farkas K.2, Banai J.3, Bene L.4, Golovics P.A.1, Gonczi L.1, Gasztonyi B.5, Kristof T.6, Lakatos L.7, Miheller P.8, Palatka K.9, Patai A.10, Papp M.9, Salamon A.11, Szamosi T.3, Szepes Z.2, Toth G.T.12, Vincze A.13, Szalay B.14, Molnar T.2, Lakatos P.L.1

1Semmelweis University, First Department of Medicine, Budapest, Hungary 2University of Szeged, First Department of Internal Medicine, Szeged, Hungary 3Military Hospital – State Health Centre, Gastroenterology, Budapest, Hungary 4Peterfy Hospital, 1st Department of Medicine, Budapest, Hungary 5Zala County Hospital, 2nd Department of Medicine, Zalaegerszeg, Hungary 6B-A-Z County and University Teaching Hospital, 2nd Department of Medicine, Miskolc, Hungary 7Csolnoky Ferenc Regional Hospital, Department of Internal Medicine, Veszprem, Hungary 8Semmelweis University, Second Departement of Internal Medicine, Budapest, Hungary 9University of Debrecen, Department of Gastroenterology, Debrecen, Hungary 10Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary 11Tolna County Teaching Hospital, Department of Gastroenterology, Szekszard, Hungary 12Janos Hospital, Department of Gastroenterology, Budapest, Hungary 13University of Pécs, 1st Department of Medicine, Pecs, Hungary 14Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapiesECCO '17 Barcelona
Year: 2017
Authors:

Hickey J.1, Keshav S.2,3, Gaugris S.4, Arasaradnam R.*5

1pH Associates, Marlow, United Kingdom 2Oxford University Hospital Trust, Oxford, United Kingdom 3John Radcliffe Hospital, Department of Gastroenterology, Oxford, United Kingdom 4Abbvie UK, Maidenhead, United Kingdom 5University Hospitals Coventry and Warwick NHS Trust, Coventry & Warwick, United Kingdom

P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Rowan C.R.*1, Alakkari A.2, Moran C.3, O'Connell J.4, Cullen G.1, Mulcahy H.1, O'Morain C.2, McNamara D.2, Leyden J.5, MacMathuna P.5, O'Toole A.3, Patchett S.3, McKiernan S.4, Kevans D.4, Doherty G.A.1, Ryan B.2

1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland 2Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Dublin, Ireland 3Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland 4St. James' Hospital, Department of Gastroenterology, Dublin, Ireland 5Mater Misericordiae University Hospital, Department of Gastroenterology, Dublin, Ireland